---
title: "300233.SZ (300233.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300233.SZ/news.md"
symbol: "300233.SZ"
name: "300233.SZ"
parent: "https://longbridge.com/en/quote/300233.SZ.md"
datetime: "2026-05-20T19:05:04.376Z"
locales:
  - [en](https://longbridge.com/en/quote/300233.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300233.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300233.SZ/news.md)
---

# 300233.SZ (300233.SZ) — Related News

### [Jincheng Pharm: The investee company VGX-3100 has reached the primary endpoint in the unblinding of its Phase III clinical trial in China](https://longbridge.com/en/news/287033163.md)
*2026-05-20T08:45:49.000Z*
> Jincheng Pharm announced that its associate company VGX-3100 has reached the primary endpoint in the Phase III clinical 

### [Jincheng Pharm: Subsidiary receives approval notice for the listing application of estradiol valerate raw materials](https://longbridge.com/en/news/286235094.md)
*2026-05-13T09:48:21.000Z*
> Jincheng Pharm announced that its wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received 

### [Jincheng Pharm: The company has secured stable supply for the flavors and fragrances it has won bids for](https://longbridge.com/en/news/284133605.md)
*2026-04-27T01:13:25.000Z*
> Jincheng Pharm (300233) stated on the interactive platform that the flavors and fragrances it has won bids for have achi

### [Jincheng Pharm released its first-quarter performance, with a net profit attributable to the parent company of 57.7945 million yuan, an increase of 64.87%](https://longbridge.com/en/news/283851142.md)
*2026-04-23T14:12:36.000Z*
> Jincheng Pharm released its first quarter report for 2026, with operating revenue of 750 million yuan, a year-on-year in

### [Jincheng Pharm: Subsidiary receives drug registration certificate for injectable lactulose erythromycin](https://longbridge.com/en/news/282314993.md)
*2026-04-10T08:50:18.000Z*
> Jincheng Pharm announced that its holding subsidiary, Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd., recently receiv

### ["A-Share Focus" Innovative drug concept is active, NEPTUNUS and other stocks hit the daily limit, WuXi AppTec AH both rose over 3%](https://longbridge.com/en/news/282119719.md)
*2026-04-09T01:49:00.000Z*
> The innovative drug concept was active in the morning session, with NEPTUNUS, JINLING PHARM., and YIBAI PHARMACEUTICAL h

### [Jincheng Pharm released its 2025 annual performance, with a net profit attributable to the parent company of 44.1863 million yuan, a decrease of 77.55%](https://longbridge.com/en/news/280643973.md)
*2026-03-26T13:51:30.000Z*
> Jincheng Pharm released its 2025 annual report, with operating revenue of 2.737 billion yuan, a year-on-year decrease of

### [Jincheng Pharm: Subsidiary receives drug registration certificates for two products](https://longbridge.com/en/news/276851551.md)
*2026-02-25T07:54:04.000Z*
> Jincheng Pharm announced that its wholly-owned subsidiary has obtained two drug registration certificates issued by the